Background: Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and
norepinephrine, was evaluated for therapeutic efficacy and safety/tolerability in the treatment …

Objective To estimate the minimum clinically important difference (MCID) for several pain
measures obtained from the Brief Pain Inventory (BPI) for patients with fibromyalgia …

Background Duloxetine is a balanced serotonin and noradrenaline reuptake inhibitor
licensed for the treatment of major depressive disorders, urinary stress incontinence and the …

PURPOSE: To assess the efficacy of fluoxetine in the treatment of patients with fibromyalgia.
SUBJECTS AND METHODS: Sixty outpatients (all women, aged 21–71 years) with …

Objective. The current analysis examines the response profile in patients receiving
duloxetine for the management of diabetic peripheral neuropathic pain (DPNP) …

Introduction: Fibromyalgia is a syndrome characterized by chronic generalized pain in
addition to different symptoms such as fatigue, sleep disturbances, stiffness, cognitive …

Duloxetine is a serotonin-norepinephrine reuptake inhibitor approved for the treatment of
patients affected by major depressive disorder (MDD), generalized anxiety disorder (GAD) …

Duloxetine has demonstrated efficacy for the treatment of major depressive disorder (MDD)
at a dose of 60 mg/day (given once daily). Whereas the target dose for the majority of …

Background: The serotonin and noradrenaline (norepinephrine) reuptake inhibitor
duloxetine has been approved in the US and elsewhere for a number of indications …

The aim of this study was to examine the longitudinal response for overall and individual
symptoms during the treatment of major depressive disorder. Data were pooled from two 9 …